AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02902939 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The cytokines modulations
Description: We should use the modification of cytokines by CytoSorb devices and cytokines removal by PMMA membranes during extracorporeal circulation in patients with risk factors of complications (long duration of extracorporeal circulation, re-do procedures and other)
Study NCT00415038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rostafuroxin
Description: 1 capusle of 50 micrograms of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
Study NCT00415038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rostafuroxin
Description: 1 capusle of 150 micrograms of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
Study NCT00415038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rostafuroxin
Description: 1 capusle of 500 micrograms of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
Study NCT00415038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rostafuroxin
Description: 1 capusle of 1.5 milligrams of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
Study NCT00415038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rostafuroxin
Description: 1 capusle of 5 milligrams of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
Study NCT03093623 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: In physical activity experimental group, trained study nurses will interview with patients,give health education,teach how to use and record the Activity meter.Professionals will calculate Metabolic Equivalent of Task(MET) with formula weekly.MET = (intensity level 9 points \* time of each exercise (hours) \* Number of times per week + moderate level 5 points \* time per activity (hours) \* number of times per week + low level 3 points \* time per activity (hours) \* number of times per week),investigators hope patients in the first month MET can reach (3.75-7.49 MET-h/ week), and reach moderate or more than moderate activity (>= 7.5-16.49 MET-h/ week) at the starting of second month for at least one year.
Study NCT03957889 — intervention group
Intervention type: OTHER
Intervention: Educational simulation
Study NCT03313375 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Exercise
Description: Subjects will be asked to perform a 45 min exercise bout. 10 minutes will be a warmup (at a work rate associated with 50% heart rate max), 30 minutes at a wattage that elicits 75-80% heart rate max, and a 5 minute cool down period, returning them to approximately 50% heart rate max.
Study NCT00808340 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A production
Description: multifocal contact lens
Study NCT00808340 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A test
Description: multifocal contact lens
Study NCT01518101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin/ Metformin
Description: Single pill combination of Vildagliptin/ Metformin (50/1000 mg).
Study NCT01518101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: 1.2 mg once daily by commercially available injection pens
Study NCT01518101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 1000 mg tablets twice daily
Study NCT03526042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Competitive blockade of AT1R-antibodies effect by binding to the angiotensin 1 receptor
Study NCT03526042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Renin-angiotensin-aldosterone system (RAAS) blockade without any effect on AT1R-antibodies effect or concentration (control group)
Study NCT01061372 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, orally administered once a day, 1-3 hours before bedtime for 12 weeks
Study NCT01061372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: pregabalin 150 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 weeks
Study NCT01061372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: pregabalin 300 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 weeks
Study NCT02284100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: animal assisted therapy
Description: For the AAT session, a 7 year old Golden Retriever was employed as the therapy animal. Prior to the study, the dog underwent rigorous screening although she had previous experience in Animal Assisted Interventions and was already trained and prepared prior for this type of work. The dog was fully vaccinated, bathed regularly, screened for enteric pathogens, and treated for internal and external parasites on a monthly basis. The dog and handler met hospital policy for participating in animal-assisted therapy, including documentation of the dog's current vaccinations, controllability and temperament.~The welfare of the dog was monitored and certificated by a dedicated veterinary during and at the end of the all sessions.
Study NCT01813747 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1440 nm wavelength laser with handpiece (Cynosure)
Description: To assess the effectiveness of device in skin tightening and laser lipolysis in the mandibular and sub-mandibular areas.
Study NCT00966368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Single dose of NN1250, formulation 1, 0.4U/kg body weight injected subcutaneously (under the skin)
Study NCT00966368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Single dose of NN1250, formulation 2, 0.4U/kg body weight injected subcutaneously (under the skin)
Study NCT06178692 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Validation of miRNA-serum signatures associated with IDH1 status
Description: Validation of miRNA-serum signatures associated with IDH1 status and prognosis, as reliable, specific and sensitive circulating diagnostic biomarkers also useful to improve prognostic stratification of patients.
Study NCT01525589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM01183
Description: PM01183 drug product (DP) is presented as a lyophilized powder for concentrate for solution for infusion with two strengths: 1 mg/vial and 4 mg/vial
Study NCT01494558 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chemoradiotherapy Regimen between PC and PE
Description: etoposide 50mg/m2 d1-5, 29-33 and cisplatin 50mg/m2 d1,8,29 and 36 29-33 during radiotherapy paclitaxel 45mg/m2 weekly and carbplatin AUC =2mg/mL/min weekly during radiotherapy
Study NCT02328612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of cells
Description: The treatment administration will be infused intravenously to the subjects after randomization:~An hour after the end of the eASCs administration, all subjects will be given an intravenous dose of LPS. Subjects will be allowed to leave in the evening once deemed clinically stable by the investigator.
Study NCT02328612 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous infusion of cells
Description: The treatment administration will be infused intravenously to the subjects after randomization:~An hour after the end of the eASCs administration, all subjects will be given an intravenous dose of LPS. Subjects will be allowed to leave in the evening once deemed clinically stable by the investigator.
Study NCT03609047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: CDK4/6 inhibitor
Study NCT03609047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel / cyclophosphamide
Description: Adjuvant Chemotherapy
Study NCT03609047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin/cyclophosphamide
Description: Adjuvant Chemotherapy
Study NCT03609047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin/cyclophosphamide
Description: Adjuvant Chemotherapy
Study NCT03609047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Adjuvant Chemotherapy
Study NCT01948245 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TaurolockTMHep100
Description: 2-4 ml of the catheter lock solution will be instilled after each infusion of parenteral nutrition/intravenous fluids varying between twice weekly to once daily, depending on the individual patients HPN programme. The instilled solution is kept in the catheter until the next infusion, with a prior flushing with 10 ml of Saline both before the instillation of the catheter lock and before infusion of HPN/fluids.
Study NCT01948245 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Heparin 100 IE/ml
Description: 2-4 ml of the catheter lock solution will be instilled after each infusion of parenteral nutrition/intravenous fluids varying between twice weekly to once daily, depending on the individual patients HPN programme. The instilled solution is kept in the catheter until the next infusion, with a prior flushing with 10 ml of Saline both before the instillation of the catheter lock and before infusion of HPN/fluids.
Study NCT03805841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tarloxotinib bromide
Description: weekly intravenous infusion
Study NCT02808988 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: periodontal phase 1 therapy
Description: periodontal phase 1 therapy consisted of scaling and root planning with ultrasonic and hand instruments under local anesthesia and gingival crevicular fluid collection by the same investigator.
Study NCT02808988 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gingival crevicular fluid collection
Description: gingival crevicular fluid collection by periopapers
Study NCT02808988 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: zoledronic acid
Description: 5 mg/year zoledronic acid (i.v.)
Study NCT06524258 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: testicular elastography
Description: testicular elastography for predicting non obstructive azoospermia
Study NCT03779555 — intervention group
Intervention type: OTHER
Intervention: Medication Event Monitoring System
Description: -Microchipped bottle cap
Study NCT00465179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: 50 mg by mouth daily for 4 weeks, then 2 weeks off.
Study NCT03297190 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS
Description: Receipt of SMS messages on nutrition and health topics
Study NCT03297190 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal Counselling
Description: Interpersonal counselling on health and nutrition topics
Study NCT04539977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: Inductive therapy: TQB2450 + EC(4 cycles) Maintenance therapy: TQB2450+EC(2 cycles) followed byTQB2450 (1 year)
Study NCT01369381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation
Description: Study patients undergo endotracheal intubation using both a conventional direct laryngoscope (Macintosh) and an alternative indirect laryngoscope (Airtraq). The order of intubation (Macintosh then Airtraq--or--Airtraq then Macintosh) is randomized.
Study NCT01369381 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation
Description: Study patients undergo endotracheal intubation using both a conventional direct laryngoscope (Macintosh) and an alternative indirect laryngoscope (Airtraq). The order of intubation (Macintosh then Airtraq--or--Airtraq then Macintosh) is randomized.
Study NCT03313375 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Interval Exercise
Description: Subjects will be asked to complete a 43 minute exercise session. To warm up, subjects will cycle at a work rate associated with 50% HRmax for 10 minutes. Wattage will then increase and subjects will do four 4-minute intervals at a work rate associated with 90%-95% HRmax, separated by 3 minutes of active recovery at a work rate associated with 50% HRmax. Subjects will be given a 5-minute cool-down period at a work rate associated with 50% HRmax.
Study NCT03888053 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BB-101
Description: Within each cohort, 8 subjects will be randomized to receive BB-101 and 4 subjects to receive placebo.
Study NCT00086671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-874/Human monoclonal antibody against IL-12
Study NCT00086671 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03608826 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational LINQ™ HF RAMware
Description: The Reveal LINQ™ device and the 2090 programmer are market-released, but once the investigational LINQ™ HF RAMware is downloaded into the devices, they are considered investigational.
Study NCT00183079 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivationally-focused brief alcohol intervention
Description: Brief, motivationally-focused alcohol intervention
Study NCT04454424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080
Description: Study intervention BAY1817080 will be administered orally with tablet(s).
Study NCT04454424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam will be administered intravenously with dose of 0.1 mg on Day 1.
Study NCT03122795 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microbiome transplant
Description: A raw microbiome, collected from a donor without any sinonasal health problems, as a nasal lavage.
Study NCT01725672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin, 500 mg extended release tablet
Description: In Part A and Part B of the study, Metformin 500 mg XR tablet will be administered with 240 millilitre (mL) water ; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
Study NCT01725672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin, 1000 mg extended release tablet
Description: In Part A and Part B of the study, Metformin 1000 mg XR tablet will be administered with 240mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
Study NCT01725672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride, 1 mg immediate release tablet
Description: In Part A and Part B of the study, Glimepiride 1 mg IR tablet will be administered with 240mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
Study NCT01725672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride, 2 mg immediate release tablet
Description: In Part A and Part B of the study, Glimepiride 2 mg IR tablet will be administered with 240mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
Study NCT01725672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin, 500 mg and Glimepiride, 1 mg extended release film coated tablet containing release controlling polymers
Description: In Part A of the study, 1 XR film coated tablet combination of Metformin 500 mg and Glimepiride 1 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
Study NCT01725672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin, 1000 mg and Glimepiride, 2 mg extended release film coated tablet containing release controlling polymers
Description: In Part A of the study, 1 XR film coated tablet combination of Metformin 1000 mg and Glimepiride 2 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
Study NCT01725672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin, 500 mg and Glimepiride, 1 mg extended release tablet coated with release controlling polymers
Description: In Part B of the study, 1 XR tablet combination of Metformin 500 mg and Glimepiride 1 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
Study NCT01725672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin, 1000 mg and Glimepiride, 2 mg extended release tablet coated with release controlling polymers
Description: In Part B of the study, 1 XR tablet combination of Metformin 1000 mg and Glimepiride 2 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
Study NCT03927170 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Janumet XR tablet 100/1000 mg
Description: To administrate the Janumet XR tablet
Study NCT03927170 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: GLH1SM tablet 100/1000 mg
Description: To administrate the GLH1SM tablet
Study NCT01705041 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diagnostics for All liver function test (LFT)
Description: HIV clinic patients meeting targeted enrollment criteria will give fingerstick blood for use on investigational LFT in comparison to routine transaminase test performed at the clinic lab (gold standard)
Study NCT00848497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testim®
Description: Testim® 5 g of gel (one tube) containing 50 mg of testosterone once daily. This was the dose given to the patient which he started.
Study NCT00848497 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Testim®
Description: Placebo Testim® 5 g of gel (one tube)
Study NCT00848497 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Viagra®
Description: Viagra 25mg was the dose given to the patient which he started.
Study NCT00848497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Viagra®
Description: Viagra 25mg was the dose given to the patient which he started.
Study NCT01104961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact lens packaging solution
Description: These test solutions are the intervention being tested.
Study NCT01104961 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Balanced salt solution (BSS)
Description: BSS is isotonic to the tissues of the eyes.
Study NCT00469131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus + steroid
Study NCT00469131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus + mycophenolate mofetil
Study NCT00671268 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AL0704rP
Description: strict subcutaneous
Study NCT00671268 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: strict subcutaneous
Study NCT00349336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 7.5mg/kg iv on day 1 of each 3 week cycle
Study NCT00349336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: As prescribed
Study NCT00349336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 5mg/kg iv on day 1 of each 2 week cycle
Study NCT00349336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX-4
Description: As prescribed
Study NCT03951519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral administration of water
Description: Volume expansion via 500 mL of water administered by the patient's nasogastric tube
Study NCT03951519 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: administration of saline solution
Description: Volume expansion via 500 mL of saline (Nacl 0.9%) administered by the venous route
Study NCT01256515 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: CDs, techniques, advice, and group training pertaining to a healthier lifestyle. Both groups will have this intervention, but the specific type of health education training will vary between groups.
Study NCT01256515 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: CDs, techniques, advice, and group training pertaining to a healthier lifestyle. Both groups will have this intervention, but the specific type of health education training will vary between groups.
Study NCT01256515 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education Training
Description: 8 weeks of group training regarding health education techniques.
Study NCT01256515 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Training
Description: 8 weeks of group training regarding health education techniques.
Study NCT04538508 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diathermy
Description: 10 sessions of 12 minutes of radiofrequency diathermy at the anterior surface of the knee, in constant movement
Study NCT04538508 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised knee exercises
Description: Daily hamstrings exercises, quadriceps exercises and hip exercises, 20 minutes of duration.
Study NCT04538508 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised knee exercises
Description: Daily hamstrings exercises, quadriceps exercises and hip exercises, 20 minutes of duration.